Analyst, Ying Huang, said, "We remain bullish as we see upside from Phase I data of the Alios nucleotide HCV polymerase inhibitors (nucs). Next key catalyst lies in the data of Kalydeco/VX-809 in cystic fibrosis patients with heterozygous F508del mutation in July."